High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer.
It is generally accepted that early detection of breast cancer has great impact on patient survival, emphasizing the importance of early diagnosis. In a widely recognized model of breast cancer development, tumor cells progress through chronological and well defined stages. However, the molecular basis of disease progression in breast cancer remains poorly understood. High-throughput molecular profiling techniques are excellent tools for the study of complex molecular alterations. By accurately mapping changes in the genome and subsequent biological/molecular pathways, the chances of finding potential novel treatment targets as well as intervention strategies are enhanced, and ultimately lives can be saved. This review provides a brief summary of recent progress in identifying molecular markers for invasiveness in early breast lesions.
Rennstam
Karin
K
Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden. Karin.Rennstam@med.lu.se
Hedenfalk
Ingrid
I
D001940:Breast / Q000503:physiopathology; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000235:genetics / Q000473:pathology; D018275:Carcinoma, Lobular / Q000235:genetics / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology; D018450:Disease Progression; D004848:Epithelium / Q000503:physiopathology; D005260:Female; D020869:Gene Expression Profiling; D005821:Genetic Techniques; D006801:Humans; D009362:Neoplasm Metastasis / Q000235:genetics; D011230:Precancerous Conditions / Q000235:genetics / Q000473:pathology; D012106:Research